AVITA Medical, Inc. (RCEL)Healthcare | Medical Devices | Valencia, United States | NasdaqCM
4.29 USD
+0.27
(6.716%)
⇧
(July 15, 2026, 11:29 a.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 2:43 a.m. EDT
The investment case for AVITA Medical is currently broken by a severe fundamental deterioration that outweighs any potential catalysts. The company is burning through cash aggressively, with operating and free cash flows both deeply negative, while carrying a debt load nearly four times its cash reserves. This precarious balance sheet is reflected in the crushing short interest of over 10%, suggesting smart money is fleeing the sinking ship. While the stock recently rallied on news of a BARDA partnership, the underlying economics remain dire with negative earnings and a massive gap between current revenue and the billions needed to service debt. The price action confirms this distress, as the stock has failed to recover from its multi-year lows despite the hype. On the options front, the heavy put positioning acts as a self-fulfilling prophecy, with traders betting against any further bounce. Until the company demonstrates a clear path to profitability or a definitive debt restructuring, this remains a high-risk speculative trap where the odds favor further capital destruction. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.051550 |
| AutoETS | 0.051587 |
| MSTL | 0.053569 |
| AutoARIMA | 0.062249 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 5.08 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.005 |
| Excess Kurtosis | 0.98 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 2.501 |
| Market Cap | 132,031,992 |
| Forward P/E | -7.25 |
| Beta | 1.86 |
| Profit Margins | -62.67% |
| Previous Name | AVITA Therapeutics, Inc. |
| Website | https://avitamedical.com |
As of July 11, 2026, 2:43 a.m. EDT: Speculators are heavily positioned for downside protection, with significant open interest in out-of-the-money puts at the $2.50 strike expiring in July and substantial in-the-money put volume at the $5.00 strike. Conversely, call activity is sparse and concentrated near the money, while speculative long-dated call volume at the $7.50 strike suggests a distant, low-probability hope for a recovery rather than immediate conviction. The implied volatility skew favors sellers, indicating the market expects continued weakness.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.24577862 |
| Address1 | 28,159 Avenue Stanford |
| Address2 | Suite 220 |
| All Time High | 55.35 |
| All Time Low | 3.22 |
| Ask | 4.29 |
| Ask Size | 1 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 313,610 |
| Average Daily Volume3 Month | 282,437 |
| Average Volume | 282,437 |
| Average Volume10Days | 313,610 |
| Beta | 1.858 |
| Bid | 3.07 |
| Bid Size | 2 |
| Board Risk | 2 |
| Book Value | -0.753 |
| City | Valencia |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.29 |
| Current Ratio | 0.475 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 4.3249 |
| Day Low | 4.02 |
| Earnings Call Timestamp End | 1,786,048,200 |
| Earnings Call Timestamp Start | 1,786,048,200 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,786,046,400 |
| Earnings Timestamp Start | 1,786,046,400 |
| Ebitda | -37,110,000 |
| Ebitda Margins | -0.51294 |
| Enterprise To Ebitda | -4.246 |
| Enterprise To Revenue | 2.178 |
| Enterprise Value | 157,581,296 |
| Eps Current Year | -1.44742 |
| Eps Forward | -0.5913441 |
| Eps Trailing Twelve Months | -1.56 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 661 367 9180 |
| Fifty Day Average | 4.2614 |
| Fifty Day Average Change | 0.02859974 |
| Fifty Day Average Change Percent | 0.006711348 |
| Fifty Two Week Change Percent | -24.577862 |
| Fifty Two Week High | 7.12 |
| Fifty Two Week High Change | -2.83 |
| Fifty Two Week High Change Percent | -0.3974719 |
| Fifty Two Week Low | 3.22 |
| Fifty Two Week Low Change | 1.0699999 |
| Fifty Two Week Low Change Percent | 0.3322981 |
| Fifty Two Week Range | 3.22 - 7.12 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,337,002,200,000 |
| Float Shares | 30,295,034 |
| Forward Eps | -0.5913441 |
| Forward P E | -7.254659 |
| Free Cashflow | -18,312,124 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 226 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.81362 |
| Gross Profits | 58,863,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01518 |
| Held Percent Institutions | 0.17156 |
| Implied Shares Outstanding | 30,776,689 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,593,475,200 |
| Last Split Factor | 1:5 |
| Long Business Summary | AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California. |
| Long Name | AVITA Medical, Inc. |
| Market | us_market |
| Market Cap | 132,031,992 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_4481298 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-15 |
| Net Income To Common | -45,339,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 123,414,522 |
| Number Of Analyst Opinions | 2 |
| Open | 4.05 |
| Operating Cashflow | -30,958,000 |
| Operating Margins | -0.45727003 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 661 367 9170 |
| Prev Name | AVITA Therapeutics, Inc. |
| Previous Close | 4.02 |
| Price Eps Current Year | -2.9638944 |
| Price Hint | 4 |
| Price To Book | -5.697211 |
| Price To Sales Trailing12 Months | 1.8249823 |
| Profit Margins | -0.62669 |
| Quick Ratio | 0.362 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.66667 |
| Region | US |
| Regular Market Change | 0.26999998 |
| Regular Market Change Percent | 6.7164173 |
| Regular Market Day High | 4.3249 |
| Regular Market Day Low | 4.02 |
| Regular Market Day Range | 4.02 - 4.3249 |
| Regular Market Open | 4.05 |
| Regular Market Previous Close | 4.02 |
| Regular Market Price | 4.29 |
| Regular Market Time | 1,784,129,340 |
| Regular Market Volume | 88,590 |
| Return On Assets | -0.40782002 |
| Revenue Growth | 0.04 |
| Revenue Per Share | 2.501 |
| Sand P52 Week Change | 0.2043345 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 30,776,689 |
| Shares Percent Shares Out | 0.082200006 |
| Shares Short | 2,529,951 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,299,835 |
| Short Name | Avita Medical, Inc. |
| Short Percent Of Float | 0.083000004 |
| Short Ratio | 7.7 |
| Source Interval | 15 |
| State | CA |
| Symbol | RCEL |
| Target High Price | 12.148761 |
| Target Low Price | 6.0736794 |
| Target Mean Price | 9.111219 |
| Target Median Price | 9.111219 |
| Total Cash | 14,261,000 |
| Total Cash Per Share | 0.463 |
| Total Debt | 48,120,000 |
| Total Revenue | 72,347,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.56 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.2047 |
| Two Hundred Day Average Change | 0.08529997 |
| Two Hundred Day Average Change Percent | 0.020286815 |
| Type Disp | Equity |
| Volume | 88,590 |
| Website | https://avitamedical.com |
| Zip | 91,355 |